1. Home
  2. G vs LQDA Comparison

G vs LQDA Comparison

Compare G & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genpact Limited

G

Genpact Limited

HOLD

Current Price

$35.17

Market Cap

5.4B

ML Signal

HOLD

LQDA

Liquidia Corporation

HOLD

Current Price

$84.11

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
G
LQDA
Founded
1997
2004
Country
Bermuda
United States
Employees
140000
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
5.5B
IPO Year
2007
2020

Fundamental Metrics

Financial Performance
Metric
G
LQDA
Price
$35.17
$84.11
Analyst Decision
Buy
Strong Buy
Analyst Count
6
11
Target Price
$49.50
$41.00
AVG Volume (30 Days)
2.0M
1.4M
Earning Date
05-07-2026
05-08-2026
Dividend Yield
2.21%
N/A
EPS Growth
9.82
51.81
EPS
0.86
0.52
Revenue
$2,279,438,000.00
$158,320,000.00
Revenue This Year
$9.20
$278.87
Revenue Next Year
$7.27
$57.13
P/E Ratio
$41.19
$167.10
Revenue Growth
N/A
1031.18
52 Week Low
$26.85
$17.82
52 Week High
$48.64
$91.10

Technical Indicators

Market Signals
Indicator
G
LQDA
Relative Strength Index (RSI) 67.18 59.67
Support Level $34.36 $70.28
Resistance Level $38.03 $91.10
Average True Range (ATR) 1.18 5.47
MACD 0.69 -0.02
Stochastic Oscillator 76.77 71.85

Price Performance

Historical Comparison
G
LQDA

About G Genpact Limited

Genpact Ltd is an agentic, technology-solutions company offering digital transformation, data-driven operations, and technology-enabled services across multiple industries. Its core business services include decision support services; technology services like application lifecycle management, platform customization, and support, etc; and digital operations optimizing business processes. Genpact also offers data engineering, data management, and domain-based AI and generative AI solutions; develops new technology solutions for clients; and offers agentic solutions and technology consulting services. Its reportable segments are: High Tech and Manufacturing, which generate maximum revenue, Financial Services, and Consumer and Healthcare. Geographically, it derives maximum revenue from India.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Share on Social Networks: